In conclusion, this study provides a practical tool for cardiovascular risk assessment in elderly RRMM patients receiving carfilzomib-based therapy, highlighting the importance of Alb levels, hypertension, renal function, and CAD. Here, ALB is linked to coronary artery disorder.